We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-5.35%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.19B
AUM Growth
+$165M
Cap. Flow
+$307M
Cap. Flow %
25.82%
Top 10 Hldgs %
50.1%
Holding
72
New
19
Increased
15
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$40.2M
2
VERV
Verve Therapeutics
VERV
+$31.5M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$29.2M
4
LENZ
LENZ Therapeutics
LENZ
+$26.6M
5
IPSC icon
Century Therapeutics
IPSC
+$25.1M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$21.6M
2
RPTX
Repare Therapeutics
RPTX
+$18.7M
3
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$10.1M
5
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$281M
$173M 14.51%
3,156,981
– –
OLMA icon
2
Olema Pharmaceuticals
OLMA
$1.06B
$105M 8.8%
3,743,875
– –
DSGN icon
3
Design Therapeutics
DSGN
$749M
$54.3M 4.57%
2,732,501
– –
VERV
4
DELISTED
Verve Therapeutics
VERV
$45.7M 3.84%
+758,265
New +$31.5M
DYN icon
5
Dyne Therapeutics
DYN
$4.2B
$43.2M 3.63%
2,054,392
-1,150,000
-36% -$21.6M
DCPH
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$40.3M 3.38%
1,100,000
+1,038,000
+1,674% +$40.2M
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$37M 3.11%
325,000
+125,000
+63% +$14.6M
LENZ
8
LENZ Therapeutics
LENZ
$182M
$32.9M 2.77%
+152,966
New +$26.6M
TIL icon
9
Instil Bio
TIL
$48.6M
$32.8M 2.76%
84,843
-7,500
-8% -$2.78M
CMPS
10
Compass Pathways
CMPS
$1.53B
$32.4M 2.73%
850,000
+600,000
+240% +$21.4M
NKTX icon
11
Nkarta
NKTX
$168M
$31.8M 2.67%
1,002,382
-258,495
-21% -$7.45M
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$31.2M 2.62%
400,000
+260,000
+186% +$19.2M
KNTE
13
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$31M 2.6%
1,329,602
+395,000
+42% +$10.1M
FMTX
14
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$30.2M 2.54%
1,215,000
-195,000
-14% -$5.24M
IOVA icon
15
Iovance Biotherapeutics
IOVA
$2.22B
$29.3M 2.46%
+1,125,000
New +$29.2M
IPSC icon
16
Century Therapeutics
IPSC
$386M
$29M 2.44%
+989,095
New +$25.1M
CYTK icon
17
Cytokinetics
CYTK
$11B
$27.7M 2.33%
1,400,000
+700,000
+100% +$16.4M
EWTX icon
18
Edgewise Therapeutics
EWTX
$4.45B
$26.3M 2.21%
1,231,812
+175,000
+17% +$4.78M
RAPT
19
CALL
DELISTED
RAPT Therapeutics
RAPT
$23.8M 2%
+93,750
New +$17.5M
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$22.1M 1.86%
+350,000
New +$18.1M
BCYC
21
Bicycle Therapeutics
BCYC
$275M
$21.7M 1.82%
715,000
-85,000
-11% -$2.57M
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$20.9M 1.75%
+939,545
New +$22.1M
BMEA icon
23
Biomea Fusion
BMEA
$92.5M
$18.1M 1.52%
+1,162,320
New +$20.5M
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$15.8M 1.33%
2,500,000
+1,300,000
+108% +$8.39M
GHRS icon
25
GH Research
GHRS
$1.92B
$15.7M 1.32%
+724,333
New +$14.8M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2021 Portfolio in Review

As of Q2 2021, Logos Global Management held 72 positions worth $1.19B, up 16% from $1.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management deployed $307M of net new capital in Q2 2021, opening 19 new positions and adding to 15 existing holdings. Its largest new stake was Verve Therapeutics: 758,265 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $21.6M trimmed.

  • Logos Global Management's largest Q2 2021 buy was Verve Therapeutics: 758,265 shares worth $45.7M.
  • Logos Global Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $40.2M increase.
  • Logos Global Management's biggest Q2 2021 reduction was Dyne Therapeutics, cutting an estimated $21.6M.
  • Logos Global Management fully exited BioXcel Therapeutics in Q2 2021, selling an estimated $17.3M.
  • Logos Global Management's ten largest holdings make up 50% of its $1.19B portfolio in Q2 2021.
  • Logos Global Management opened 19 new positions and closed 14 in Q2 2021.
  • Logos Global Management's portfolio value rose 16% quarter-over-quarter to $1.19B.

Based on Logos Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.